ClearPoint Neuro, Inc. (CLPT) stock intrinsic value fair value estimate & owner earnings analysis

ClearPoint Neuro makes equipment and single-use devices that let neurosurgeons place instruments precisely inside the brain. Its ClearPoint system (the SmartFrame trajectory guide, navigation software and disposables) was built for MRI-guided procedures and since 2021 has moved into the operating room with SmartFrame Array, the SmartFrame OR system (2024) and Navigation Software 3.0 (2025). It also sells the Prism laser ablation system, made for it by CLS, and, since buying IRRAS in November 2025, the IRRAflow system that irrigates and drains blood from the brain in neurocritical care. About half of revenue comes from drug-delivery partners: more than 60 pharmaceutical, biotech and academic groups use its SmartFlow Neuro cannula and its preclinical services to inject gene and cell therapies into the brain. In 2024 the FDA authorized the cannula for delivering PTC Therapeutics' gene therapy for AADC deficiency; PTC was about 15% of drug-delivery revenue in 2025. Revenue has grown steadily, from $11.2M in 2019 to $37.0M in 2025 (about 22% a year), and reached $23.0M in the first half of 2026, up 30%, helped by IRRAS. Gross margin is healthy at 61-63%. The problem is that costs have grown almost as fast. Measured as the cash the business actually produces for its owners - operating cash flow with working-capital timing removed, less stock compensation (which we treat as a real cost) and the capital spending needed to keep the business running - ClearPoint has lost money in every one of the last ten years: about $14M in 2021, $17M in 2022, $21M in 2023, $18M in 2024 and $24M in 2025 (roughly $0.66 to $0.85 per share). We use 2021-2025, the period since the move into the operating room and services, as the representative window; the median is a loss of about $0.69 per share, or roughly $18M a year. In 2025 we set aside a one-time $7.5M paydown of liabilities taken on with IRRAS, which the company says will not recur. The first half of 2026 was worse, not better: a loss of about $19M in six months even as revenue rose 30%, reflecting the added IRRAS cost base and interest on new debt. With losses having widened about 30% in 2025, our base case assumes they widen again in 2026 (to about $35M) rather than improve. The business runs on outside money. In 2025 it borrowed $50M from an affiliate of Oberland Capital under notes that mature six years after each draw (May and November 2031), carry interest of 8.25-9.5% (half paid in additional notes for the first six quarters), pay the lender a small share of revenue from 2027, and require premiums of 117.5-135% if repaid early or on a change of control. Cash was $45.9M at the end of 2025 and $29.4M at June 30, 2026. The annual report concluded the company had enough cash for the following twelve months, and a $50M at-the-market share program is available, but at the current burn rate further share sales or borrowing look likely within about a year, which dilutes existing owners. Because every future year of losses must be paid for with new shares or new debt, a case in which losses persist is worth less than nothing to today's shareholders: each current share effectively carries its portion of the future funding need, and the lender ranks ahead of the shares. Bear case (about -$12.40 per share): Drug-delivery services stay flat, as they did in 2025 ($11.7M in both years), capital equipment sales keep shrinking (down 18% in 2025), and dependence on a few pharma customers such as PTC works against it, so revenue grows about 12% a year with gross margin near 60%. Operating costs keep rising about 10% a year. Losses widen from about $35M in 2026 to more than $70M by 2035 and the business never funds itself. Ten years of such losses total roughly $375M in today's money - in this case the company would need about $12 per current share more from its funders than the business can ever return. Base case (about -$9.00 per share): Revenue compounds near its record, about 20% a year through 2030 and 12% after, gross margin holds at 62%, and operating costs grow about 12% a year and then 6% - a wider gap between revenue growth and cost growth than the company actually achieved over 2021-2025. Even so, because operating costs start at roughly twice gross profit, losses stay near $35-40M a year through 2031 and are still about $28M in 2035; break-even arrives only late in the 2030s. The present value of ten years of losses is about $270M, roughly $9 per current share of funding that owners will bear through dilution. We add no value after 2035 because the business has not yet shown positive earning power that could be carried forward. Bull case (about $5.25 per share): 2024 becomes the pattern rather than the exception - that year revenue grew 31% while operating costs rose about 8%. Products already launched (SmartFrame OR, Navigation 3.0, and IRRAflow sold into the same neurosurgery accounts) and growing disposable use lift revenue about 27% a year through 2030 and 15% after, gross margin improves to 64%, and operating costs grow only 8% and then 6%. ClearPoint turns positive in 2031 and earns about $57M by 2035; beyond that we let earnings fade to zero over fifteen years, supported by recurring disposable sales on its installed base. We did not include a windfall from a partner's gene therapy being approved for a large disease such as Parkinson's or Huntington's: the filings name no specific program or approval date. Such an approval would lift this case materially. Accounting judgements: stock compensation ($8.2M in 2025) is deducted as a real cost. Amortization of the intangible assets bought with IRRAS is added back as a non-cash charge; because that purchased technology wears out, we credit it with no value beyond the growth assumed in each case. Capital spending is small, about 1% of revenue, so the split between maintenance and growth spending barely matters. Owner earnings reconcile to net loss plus non-cash charges in every year checked. What would make this estimate wrong: two or three years like 2024 in a row, with revenue growing far faster than costs, would move the likely outcome toward the bull case, and approval of a partner therapy delivered with the SmartFlow cannula in a large indication could add substantial disposable and service revenue. On the other side, failure to raise money on acceptable terms, or a default under the notes, would leave shareholders behind a lender with a claim above $50M. A margin-of-safety price applies only once the business shows it can fund itself, and then only at a level that leaves a wide margin for a small, leveraged company that has never earned money for its owners.